- Home
- PRME vs EYPT Comparison
PRME vs EYPT Comparison
Compare PRME & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRME | EYPT |
|---|---|---|
| Founded | 2019 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 1.5B |
| IPO Year | 2022 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PRME | EYPT |
|---|---|---|
| Price | $3.50 | $18.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $6.42 | ★ $29.60 |
| AVG Volume (30 Days) | ★ 3.8M | 1.3M |
| Earning Date | 11-07-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,977,000.00 | ★ $42,339,000.00 |
| Revenue This Year | $111.80 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 647.13 | N/A |
| 52 Week Low | $1.11 | $3.91 |
| 52 Week High | $6.94 | $19.11 |
Technical Indicators
Market Signals| Indicator | PRME | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 66.55 |
| Support Level | $3.61 | $16.52 |
| Resistance Level | $4.12 | $19.00 |
| Average True Range (ATR) | 0.28 | 1.01 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 3.14 | 74.24 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.